P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

por Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie-Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.
Publicado 2022

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

por Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie-Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.
Publicado 2022

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

por Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie-Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.
Publicado 2022